These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 15231437

  • 21. Attenuated neural response to gamble outcomes in drug-naive patients with Parkinson's disease.
    van der Vegt JP, Hulme OJ, Zittel S, Madsen KH, Weiss MM, Buhmann C, Bloem BR, Münchau A, Siebner HR.
    Brain; 2013 Apr; 136(Pt 4):1192-203. PubMed ID: 23442226
    [Abstract] [Full Text] [Related]

  • 22. Placebo neural systems: nitric oxide, morphine and the dopamine brain reward and motivation circuitries.
    Fricchione G, Stefano GB.
    Med Sci Monit; 2005 May; 11(5):MS54-65. PubMed ID: 15874901
    [Abstract] [Full Text] [Related]

  • 23. Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders.
    Di Matteo V, Pierucci M, Esposito E, Crescimanno G, Benigno A, Di Giovanni G.
    Prog Brain Res; 2008 May; 172():423-63. PubMed ID: 18772045
    [Abstract] [Full Text] [Related]

  • 24. Parkinson's disease duration determines effect of dopaminergic therapy on ventral striatum function.
    MacDonald AA, Monchi O, Seergobin KN, Ganjavi H, Tamjeedi R, MacDonald PA.
    Mov Disord; 2013 Feb; 28(2):153-60. PubMed ID: 23165957
    [Abstract] [Full Text] [Related]

  • 25. Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling.
    Cilia R, Ko JH, Cho SS, van Eimeren T, Marotta G, Pellecchia G, Pezzoli G, Antonini A, Strafella AP.
    Neurobiol Dis; 2010 Jul; 39(1):98-104. PubMed ID: 20338240
    [Abstract] [Full Text] [Related]

  • 26. The placebo response: how words and rituals change the patient's brain.
    Benedetti F, Amanzio M.
    Patient Educ Couns; 2011 Sep; 84(3):413-9. PubMed ID: 21621366
    [Abstract] [Full Text] [Related]

  • 27. Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease.
    Freeman TB, Vawter DE, Leaverton PE, Godbold JH, Hauser RA, Goetz CG, Olanow CW.
    N Engl J Med; 1999 Sep 23; 341(13):988-92. PubMed ID: 10498497
    [No Abstract] [Full Text] [Related]

  • 28. Cortico-basal ganglia-cortical circuitry in Parkinson's disease reconsidered.
    Braak H, Del Tredici K.
    Exp Neurol; 2008 Jul 23; 212(1):226-9. PubMed ID: 18501351
    [Abstract] [Full Text] [Related]

  • 29. The placebo effect: why we should care.
    Tausk F, Ader R, Duffy Smith N.
    Clin Dermatol; 2013 Jul 23; 31(1):86-91. PubMed ID: 23245979
    [Abstract] [Full Text] [Related]

  • 30. Placebo surgery in trials of therapy for Parkinson's disease.
    Freed CR, Breeze RE, Fahn S.
    N Engl J Med; 2000 Feb 03; 342(5):353-4; author reply 354-5. PubMed ID: 10660397
    [No Abstract] [Full Text] [Related]

  • 31. Impact of placebo assignment in clinical trials of Parkinson's disease.
    Goetz CG, Janko K, Blasucci L, Jaglin JA.
    Mov Disord; 2003 Oct 03; 18(10):1146-9. PubMed ID: 14534918
    [Abstract] [Full Text] [Related]

  • 32. New insights into the placebo and nocebo responses.
    Enck P, Benedetti F, Schedlowski M.
    Neuron; 2008 Jul 31; 59(2):195-206. PubMed ID: 18667148
    [Abstract] [Full Text] [Related]

  • 33. Understanding the dopaminergic deficits in Parkinson's disease: insights into disease heterogeneity.
    Lewis SJ, Barker RA.
    J Clin Neurosci; 2009 May 31; 16(5):620-5. PubMed ID: 19285870
    [Abstract] [Full Text] [Related]

  • 34. The placebo response in clinical trials-the current state of play.
    Enck P, Klosterhalfen S.
    Complement Ther Med; 2013 Apr 31; 21(2):98-101. PubMed ID: 23497810
    [Abstract] [Full Text] [Related]

  • 35. Placebo: new insights into an old enigma.
    Ernst E.
    Drug Discov Today; 2007 May 31; 12(9-10):413-8. PubMed ID: 17467578
    [Abstract] [Full Text] [Related]

  • 36. Mapping neuronal activity of the basal ganglia in experimental models of Parkinson's disease: contributions of the [14C]2-deoxyglucose method.
    Orzi F, Fornai F, Blandini F.
    Funct Neurol; 2000 May 31; 15(4):269-76. PubMed ID: 11213530
    [No Abstract] [Full Text] [Related]

  • 37. Placebo surgery in trials of therapy for Parkinson's disease.
    Horisberger JD.
    N Engl J Med; 2000 Feb 03; 342(5):354-5. PubMed ID: 10660399
    [No Abstract] [Full Text] [Related]

  • 38. Harnessing the power of placebos in movement disorders: Insights from Parkinson's disease in clinical research and practice.
    Mestre TA, Shamy M, Benedetti F, Lang AE.
    Mov Disord; 2018 Aug 03; 33(8):1195-1203. PubMed ID: 30145820
    [Abstract] [Full Text] [Related]

  • 39. Selective impairment of prediction error signaling in human dorsolateral but not ventral striatum in Parkinson's disease patients: evidence from a model-based fMRI study.
    Schonberg T, O'Doherty JP, Joel D, Inzelberg R, Segev Y, Daw ND.
    Neuroimage; 2010 Jan 01; 49(1):772-81. PubMed ID: 19682583
    [Abstract] [Full Text] [Related]

  • 40. Striatal and extrastriatal dopamine in the basal ganglia: an overview of its anatomical organization in normal and Parkinsonian brains.
    Smith Y, Villalba R.
    Mov Disord; 2008 Jan 01; 23 Suppl 3():S534-47. PubMed ID: 18781680
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.